LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. raised its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 3.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 54,738 shares of the medical instruments supplier’s stock after buying an additional 1,678 shares during the quarter. Victory Capital Management Inc. owned about 0.24% of LeMaitre Vascular worth $5,044,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. lifted its position in LeMaitre Vascular by 2.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 195,752 shares of the medical instruments supplier’s stock valued at $18,037,000 after buying an additional 4,241 shares during the last quarter. Jones Financial Companies Lllp lifted its position in shares of LeMaitre Vascular by 2.8% during the fourth quarter. Jones Financial Companies Lllp now owns 6,987 shares of the medical instruments supplier’s stock worth $644,000 after purchasing an additional 187 shares in the last quarter. Norden Group LLC lifted its position in shares of LeMaitre Vascular by 4.5% during the fourth quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier’s stock worth $218,000 after purchasing an additional 103 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in shares of LeMaitre Vascular by 234.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 293 shares in the last quarter. Finally, Flputnam Investment Management Co. lifted its position in shares of LeMaitre Vascular by 3.6% during the fourth quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier’s stock worth $269,000 after purchasing an additional 102 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Analyst Ratings Changes

LMAT has been the topic of several research reports. Oppenheimer cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price on the stock. Lake Street Capital upped their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Finally, Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Five analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, LeMaitre Vascular presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.25.

Insiders Place Their Bets

In other news, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the transaction, the insider now directly owns 5,564 shares of the company’s stock, valued at $456,915.68. The trade was a 26.53 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 10.79% of the stock is owned by corporate insiders.

LeMaitre Vascular Trading Up 3.9 %

LMAT stock opened at $81.91 on Friday. LeMaitre Vascular, Inc. has a twelve month low of $62.39 and a twelve month high of $109.58. The company’s 50 day moving average is $95.21 and its two-hundred day moving average is $94.63. The stock has a market cap of $1.85 billion, a P/E ratio of 44.76, a PEG ratio of 2.22 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company had revenue of $55.81 million for the quarter, compared to analysts’ expectations of $55.99 million. On average, equities research analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th will be issued a dividend of $0.20 per share. The ex-dividend date is Thursday, March 13th. This represents a $0.80 dividend on an annualized basis and a yield of 0.98%. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 41.24%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.